1. Home
  2. GO vs ACRS Comparison

GO vs ACRS Comparison

Compare GO & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grocery Outlet Holding Corp.

GO

Grocery Outlet Holding Corp.

HOLD

Current Price

$9.01

Market Cap

884.4M

ML Signal

HOLD

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$5.23

Market Cap

748.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GO
ACRS
Founded
1946
2012
Country
United States
United States
Employees
2207
N/A
Industry
Food Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
884.4M
748.6M
IPO Year
2019
2015

Fundamental Metrics

Financial Performance
Metric
GO
ACRS
Price
$9.01
$5.23
Analyst Decision
Hold
Strong Buy
Analyst Count
10
5
Target Price
$11.30
$10.20
AVG Volume (30 Days)
2.1M
1.8M
Earning Date
05-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.01
EPS
N/A
N/A
Revenue
$4,688,759,000.00
$1,683,000.00
Revenue This Year
$2.48
N/A
Revenue Next Year
$3.91
$4.24
P/E Ratio
N/A
N/A
Revenue Growth
7.26
N/A
52 Week Low
$5.66
$1.46
52 Week High
$19.41
$5.88

Technical Indicators

Market Signals
Indicator
GO
ACRS
Relative Strength Index (RSI) 39.33 49.39
Support Level $9.01 $4.13
Resistance Level $10.54 $5.85
Average True Range (ATR) 0.37 0.31
MACD -0.16 -0.05
Stochastic Oscillator 13.54 2.34

Price Performance

Historical Comparison
GO
ACRS

About GO Grocery Outlet Holding Corp.

Grocery Outlet Holding Corp is a grocery store operator in the United States. It is a retailer of quality, name-brand consumables and fresh products sold through a network of independently operated stores. The stores are run by Entrepreneurial independent operators which create a neighborhood feel through personalized customer service and a localized product offering.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Share on Social Networks: